Here’s what you should know:
1. The company’s revenues increased 6 percent year-over-year.
2. U.S. revenues also increased 7 percent accounting for $2.9 billion of the total revenues.
3. Bristol-Myers Squibb’s Opdivo and Eliquis had strong sales over the quarter contributing to the increased revenues.
4. The company’s net earnings were $916 million, or $0.56 per share.
5. Concerning rest-of-year outlooks, Bristol-Myers Squibb decreased its earnings per share range estimates from $2.72 to $2.87 originally to $2.66 to $2.76.
More articles on gastroenterology:
Eisai submits liver cancer treatment application to FDA — 5 notes
GI center to know: Illinois Gastroenterology Institute
Capital Digestive Care adds 2 physicians & more: 5 GI practices in the news
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
